Novel biologics for cancer therapy

Despite recent successful CAR-T outcomes in liquid tumors, its effect on solid tumors has not been achieved. This is mostly because the immunosuppressive tumor microenvironment inhibits the functions of T cells. Here, we have designed a novel biologic, which interacts with tumors in a different manner, that overcomes the CAR-T therapies’ limitations. This novel cancer-elimination mechanism is independent of inherent immune functions, such that it would not be inhibited by the tumor microenvironment. Our technology opens up brand new approaches for engineered cells to eliminate cancer.